{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:27:10Z","timestamp":1771673230268,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidsponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jisp.2017.10.005","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T04:10:54Z","timestamp":1513656654000},"page":"S62-S64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cytokine Targeted Therapeutics for\u00a0Alopecia Areata: Lessons from\u00a0Atopic Dermatitis and Other\u00a0Inflammatory Skin Diseases"],"prefix":"10.1016","volume":"19","author":[{"given":"Kunal","family":"Malik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jisp.2017.10.005_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4103\/2229-5178.131076","article-title":"Total serum immunoglobulin E in patients with alopecia areata","volume":"5","author":"Bakry","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jisp.2017.10.005_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2009.04.031","article-title":"History of atopy or autoimmunity increases risk of alopecia areata","volume":"61","author":"Barahmani","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jisp.2017.10.005_bib4","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/sj.jid.5700915","article-title":"Loss-of-function mutations in the filaggrin gene and alopecia areata: strong risk factor for a severe course of disease in patients comorbid for atopic disease","volume":"127","author":"Betz","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1523-1747.2002.01811.x","article-title":"Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans","volume":"119","author":"Carroll","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.08.032","article-title":"Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study","volume":"65","author":"Chu","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib8","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1529-8019.2011.01413.x","article-title":"Alopecia areata: clinical presentation, diagnosis, and unusual cases","volume":"24","author":"Finner","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jisp.2017.10.005_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Fuentes-Duculan","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib11","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jisp.2017.10.005_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","article-title":"Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism","volume":"137","author":"Guttman-Yassky","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jisp.2017.10.005_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jisp.2017.10.005_bib15","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/jid.2012.129","article-title":"Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance","volume":"132","author":"Jagielska","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.gene.2013.05.086","article-title":"The association between interleukin (IL)-4 gene intron 3 VNTR polymorphism and alopecia areata (AA) in Turkish population","volume":"527","author":"Kalkan","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.jisp.2017.10.005_bib17","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jisp.2017.10.005_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdermsci.2014.11.009","article-title":"The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in\u00a0vivo","volume":"77","author":"Keren","year":"2015","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jisp.2017.10.005_bib19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jisp.2017.10.005_bib20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5021\/ad.2014.26.6.722","article-title":"Differences in comorbidity profiles between early-onset and late-onset\u00a0alopecia areata patients: a retrospective study of 871 Korean patients","volume":"26","author":"Lee","year":"2014","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jisp.2017.10.005_bib22","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"issue":"Suppl 2","key":"10.1016\/j.jisp.2017.10.005_bib23","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jisp.2017.10.005_bib24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14712598.2016.1188076","article-title":"A\u00a0novel therapeutic paradigm for patients with extensive alopecia areata","volume":"16","author":"Renert-Yuval","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jisp.2017.10.005_bib25","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A\u00a0pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib26","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jisp.2017.10.005_bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Suarez-Farinas","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jisp.2017.10.005_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygeno.2010.05.002","article-title":"Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures","volume":"96","author":"Subramanya","year":"2010","journal-title":"Genomics"},{"key":"10.1016\/j.jisp.2017.10.005_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjd.12396","article-title":"T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata","volume":"169","author":"Tembhre","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jisp.2017.10.005_bib30","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"}],"container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002417300370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002417300370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T21:20:13Z","timestamp":1546291213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1087002417300370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1087002417300370"],"URL":"https:\/\/doi.org\/10.1016\/j.jisp.2017.10.005","relation":{},"ISSN":["1087-0024"],"issn-type":[{"value":"1087-0024","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine Targeted Therapeutics for\u00a0Alopecia Areata: Lessons from\u00a0Atopic Dermatitis and Other\u00a0Inflammatory Skin Diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology Symposium Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jisp.2017.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}